Multiple Myeloma Research Consortium claims it accelerates clinical trial process

The Multiple Myeloma Research Consortium (MMRC) says that clinical trials conducted within the Consortium open 60% faster than the industry benchmark in oncology, complete clinical trial enrollment two months (14%) earlier than the expected timeline, and enroll 25% more patients than the original MMRC commitment.

These data are based on a retrospective review of 21 multiple myeloma trials conducted with MMRC project management resources from May 2006 to June 2010. The MMRC trial performance results were presented at the American Society of Hematology (ASH) annual meeting being held in Orlando, Florida.

“The MMRC provides strategic solutions that have contributed toward the development of our selective proteasome inhibitor carfilzomib, including rapid accrual of patients and access to its network of institutions,” said Michael Kauffman, chief medical officer of the drug’s developer, Onyx Pharmaceuticals, adding: “We are grateful for the MMRC’s commitment to patients and for helping advance carfilzomib.”